藥明系股價未止跌 藥明康德(02359.HK)及藥明生物(02269.HK)續挫5%-6.5%
藥明系股價繼昨天急挫後,今天跌勢未止,藍籌藥明康德(02359.HK)及藥明生物(02269.HK)低見42.35元及14.82元,現報42.7元及15.04元,續挫5%及6.5%,成交分別為991萬股及7,736萬股。
藥明合聯(02268.HK)三連跌,高低見16.46元/15.42元,現報15.92元,反覆跌1.7%。
美國生物技術創新組織(BIO)轉(車太)支持《生物安全法案》,並採取措施剔除藥明康德的會員資格。藥明康德亦致函BIO,稱會終止在BIO的會員資格。
道瓊斯引述野村中國醫療健康研究部主管張佳林表示,在目前階段,藥明康德失去會員資格並不一定意味著失去業務,更多的是可能失去該組織提供的游說支持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.